The predictive value of liver tests for the presence of liver metastases.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2023-10-12 eCollection Date: 2023-09-01 DOI:10.2217/hep-2023-0003

Alexandra V Kimchy, Harjit Singh, Esha Parikh, Jessica Rosenberg, Kavya Sanghavi, James H Lewis

引用次数: 0

Abstract

Aim: To analyze the predictive value of biochemical liver tests in patients with malignant melanoma, breast, colorectal or lung cancers at the time of diagnosis of liver metastases.

Methods: A retrospective review of patients with the above-mentioned solid tumors at MedStar Georgetown University Hospital from 2016-2020.

Results: The highest optimal cutoff according to sensitivity and specificity for the presence of liver metastases was for AST ≥1.5 × ULN for melanoma, lung, and breast cancers and ≥2 × ULN for colorectal cancer, ALT ≥1.25 × ULN for melanoma, breast and colorectal cancers and ≥1.5 × ULN for lung cancer, and ALP ≥1.5 × ULN for melanoma, breast and colorectal cancers.

Conclusion: Using thresholds of liver enzymes above the ULN may improve the diagnostic accuracy for the presence of liver metastases.

查看原文本刊更多论文

肝脏检查对肝转移的预测价值。

目的：分析肝生化检查在诊断肝转移时对恶性黑色素瘤、乳腺癌、结直肠癌或肺癌患者的预测价值。方法：对2016年至2020年在美国乔治城大学MedStar医院患有上述实体瘤的患者进行回顾性审查。结果：根据肝转移的敏感性和特异性，黑色素瘤、肺癌和乳腺癌AST≥1.5×ULN，结直肠癌癌症ALT≥2×ULN；黑色素瘤ALT≥1.25×ULN，乳腺癌和结直肠癌，癌症≥1.5×ULN，黑色素瘤、乳腺癌和结直肠癌ALP≥1.5×ULN。结论：应用ULN以上的肝酶阈值可以提高肝转移瘤的诊断准确性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.